Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 165-176 , June 2008

Prophylaxis of acute GVHD: manipulate the graft or the environment?

  • A. John Barrett, MD, FRCP, FRCPath (UK) (Chief, Stem Cell Allotransplantation Section)
  • Katarina Le Blanc, MD, PhD (Professor of Clinical Stem Cell Research, Hematology Center)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +46 8 585 89463; Fax: +46 8 746 6699.

References 

  1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures. 1966–1967;62:21–78
  2. Hensel N, Agarwala V, Jiang YZ, et al. A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. Bone Marrow Transplantation. 1999;23:71–78
  3. Holler E. Risk assessment in haematopoietic stem cell transplantation: GVHD prevention and treatment. Best Practice & Research. Clinical Haematology. 2007;20:281–294
  4. Barrett AJ, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplantation. 1998;21:543–545
  5. Elhasid R, Arush MB, Zaidman I, et al. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis. Biology of Blood and Marrow Transplantaion. 2007;13:329–338
  6. Drobyski WR, Hessner MJ, Klein JP, et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood. 1999;94:434–441
  7. Kalaycio M, Rybicki L, Pohlman B, et al. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplantation. 2005 Feb;35(3):247–252
  8. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood. 2007 Jan 1;109(1):374–382
  9. Bishop MR, Steinberg SM, Gress RE, et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. British Journal of Haematology. 2004;126:837–843
  10. Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2005;7:109–115
  11. André-Schmutz I, Le Deist F, Hacein-Bey-Abina S, et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet. 2002;360:130–137
  12. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005;106:1123–1129
  13. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15;102(6):2292–2299
  14. Mielke S, Nunes R, Rezvani K, et al. A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood. 2007 Sep 24;[e pub]
  15. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 2006;107:1828–1836
  16. Bonini C, Bondanza A, Perna SK. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Molecular Therapy. 2007;15(7):1248–1252
  17. Schmitz N, Barrett J. Optimizing engraftment–source and dose of stem cells. Seminars in Hematology. 2002;39:3–14
  18. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose?. Bone Marrow Transplantation. 2003;31:839–845
  19. Ruggeri L, Mancusi A, Burchielli E, et al. Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy. 2006;8(6):554–558
  20. Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007 Oct;21(10):2145–2152
  21. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051–3057
  22. Koç ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Journal of Clinical Oncology. 2000;18(2):307–316
  23. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation. 2005;11(5):389–398
  24. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733–1738
  25. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110(7):2764–2767
  26. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441
  27. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81(10):1390–1397
  28. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;73(6):1729–1734
  29. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood. 1993;81(4):1094–1101
  30. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77(7):1423–1428
  31. Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95(5):1572–1579
  32. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062–2068
  33. Le Blanc K, Remberger M, Uzunel M, et al. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation. 2004;78(7):1014–1020
  34. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clinical Pharmacology & Therapeutics. 2007;82(4):381–388
  35. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7):3108–3114
  36. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology. 2007;139:70–80
  37. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–1394
  38. Ogawa H, Ikegame K, Yoshihara S, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation. 2006 Oct;12(10):1073–1084
  39. Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biology of Blood and Marrow Transplantation. 2007;13:1499–1507
  40. Remberger M, Mattsson J, Hassan Z, et al. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors-a single centre study. Bone Marrow Transplantation. 2007 Nov 5;[epub ahead of print]
  41. Hirshfeld E, Weiss L, Kasir J, et al. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?. Bone Marrow Transplantation. 2006;38:359–364
  42. Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007 Apr 1;109(7):3115–3123
  43. Salomon BL, Sudres M, Cohen JL. Regulatory T cells in graft-versus-host disease. Springer Seminars in Immunopathology. 2006;28:25–29[review]
  44. Mielke S, Rezvani K, Savani BN, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood. 2007 Sep 1;110(5):1689–1697
  45. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood. 2006;15(108):1291–1297
  46. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105:2227–2234
  47. Dimitroff CJ, Kupper TS, Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. The Journal of Clinical Investigation. 2003;112:980–983
  48. Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplantation. 2005 Mar;35(Suppl. 1):S53–S57
  49. Barrett J. Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Current Opinion in Immunology. 2006;18:592–598

PII: S1521-6926(08)00005-4

doi: 10.1016/j.beha.2008.02.004

Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 165-176 , June 2008

Article Tools

* Image Usage & Resolution